SCHEMBL2924853

SCHEMBL2924853

CCCN1CCN(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
DRD2 P14416 7/20 0.53
SIGMAR1 Q99720 3/20 0.53
ADRB1 P08588 1/20 0.53
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46
THPO P40225 1/20 0.46
MTOR P42345 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
DPP4 P27487 1/20 0.46
HTR1A P08908 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923960 0.91 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2DRD2SIGMAR1ADRB1
SCHEMBL10104322 0.91 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2DRD2SIGMAR1ADRB1
SCHEMBL2927915 0.90 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2DRD2SIGMAR1ADRB1
SCHEMBL2928287 0.86 ADRB1 (0.56) ALDH1A1SMN1; SMN2SIGMAR1ADRB1CYP1A2
SCHEMBL2927397 0.84 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2DRD2SIGMAR1CYP1A2
SCHEMBL13080288 0.83 DRD2 (0.62) ALDH1A1SMN1; SMN2DRD2SIGMAR1HTR1A
SCHEMBL2098119 0.83 ADRB1 (0.53) ALDH1A1SMN1; SMN2DRD2SIGMAR1ADRB1
SCHEMBL11748600 0.83 ADRB1 (0.53) ALDH1A1SMN1; SMN2DRD2SIGMAR1ADRB1
Ammonia Solution, Strong SCHEMBL11284383 0.83 ALDH1A1 (0.75) ALDH1A1SMN1; SMN2DRD2SIGMAR1CYP1A2
SCHEMBL28692744 0.83 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2DRD2SIGMAR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE41315-E1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) 2010-05-04 US disclosed
US-6924374-B2 Central nervous system disorders; psychological disorders A. CARLSSON RESEARCH AB (SE) 2005-08-02 US disclosed
EP-1419773-A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission A. Carlsson Research AB (SE) 2004-05-19 EP disclosed
US-20030004169-A1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004169-A1 Modulators of dopamine neurotransmission OPRD1, OPRK1, OPRM1 ALDH1A1 2318/4885SMN1; SMN2 904/4885DRD2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.